FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of medicine, in particular to pharmacology and represents a pharmaceutical composition with antipsychotic action, including as active ingredient therapeutically effective amount of methyl ether N-caproyl-L-prolyl-L-tyrosine, and as auxiliary substance, at least, one substance, selected from the group, including starch, lactose and auxiliary substances on its base, microcrystalline cellulose (MCC), aerosil, modified starches, calcium phosphate twice-substituted, polyvinyl pyrrolidone, methylcellulose, carboxymethylcellulose, and its sodium salt, oxypropylmethylcellulose, mannitol, sorbitol, stearic acid and/or its salt.
EFFECT: invention provides creation of neuroleptic, not depressing cognitive functions even improving them.
19 cl, 25 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION WITH PROLONGED RELEASE WITH ANTIPSYCHOTIC ACTIVITY AND SYNTHESIS METHODS THEREOF | 2012 |
|
RU2584653C2 |
| PHARMACEUTICAL COMPOSITION WITH ANTIMIGRAINE ACTION (VERSIONS) | 2008 |
|
RU2424803C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2423981C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISORDERS AND METHODS FOR PREPARING THEM | 2012 |
|
RU2559776C2 |
| PHARMACEUTICAL COMPOSITION IN SOLID FORM WITH ANALGESIC ACTIVITY | 2013 |
|
RU2545861C1 |
| PHARMACEUTICAL COMPOSITIONS WITH PROLONGED RELEASE FOR TREATING CEREBROVASCULAR DISORDERS | 2014 |
|
RU2611339C2 |
| PHARMACEUTICAL COMPOSITION BASED ON LADASTEN | 2006 |
|
RU2376986C2 |
| PHARMACEUTICAL COMPOSITION OF N-(6-PHENYLHEXANOYL)GLYCYL-L-TRYPTOPHAN AMIDE IN SOLID DOSAGE FORM | 2013 |
|
RU2602742C2 |
| PROLONGED ACTION PREPARATION OF DICLOFENAC SODIUM | 2002 |
|
RU2221559C1 |
| "NOOPEPT"-BASE PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2289422C2 |
Authors
Dates
2011-06-10—Published
2009-01-15—Filed